Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder

Drug Safety

Volumn 33, Issue 10, 2010, Pages 821-842

  Besag, Frank M C ^b   Stiefel, Gary ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b Twinwoods Health Resource Centre ^*  (United Kingdom)

Author keywords

Adolescents; Amphetamines, adverse reactions; Atomoxetine, adverse reactions; Attention deficit hyperactivity disorder; Blood pressure; Cardiovascular abnormalities, drug induced; Children; ECG abnormalities, drug induced; Heart rate; Methylphenidate, adverse reactions; QT interval prolongation, drug induced; Sudden death, drug induced

Indexed keywords

AMPHETAMINE; AMPHETAMINE DERIVATIVE; ATOMOXETINE; DEXAMPHETAMINE; LISDEXAMFETAMINE; METHYLPHENIDATE;

ATTENTION DEFICIT DISORDER; CARDIOVASCULAR EFFECT; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DOSE TIME EFFECT RELATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; HEART LEFT ANTERIOR BUNDLE BRANCH BLOCK; HEART MURMUR; HEART RATE; HEART RIGHT BUNDLE BRANCH BLOCK; HUMAN; HYPERTENSION; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; QT DISPERSION; QT INTERVAL; QT PROLONGATION; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SINUS ARRHYTHMIA; SUDDEN DEATH; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; WOLFF PARKINSON WHITE SYNDROME;

ADRENERGIC UPTAKE INHIBITORS; AMPHETAMINES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM STIMULANTS; ELECTROCARDIOGRAPHY; HEART RATE; HUMANS; METHYLPHENIDATE; PROPYLAMINES;

EID: 77956321130     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11536380-000000000-00000     Document Type: Review

References (69)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed, text revision. Washington, DC: American Psychiatric Association, 2000
2. Ford T, Goodman R, Meltzer H. The British child and adolescent mental health survey 1999: the prevalence of DSM-IV disorders. J Am Acad Child Adolesc Psychiatry 2003 Oct; 42 (10): 1203-1211
3. World Health Organization. International classification of diseases. 10th ed. Geneva: World Health Organization, 1992
4. National Institute for Health and Clinical Excellence. CG72 attention deficit hyperactivity disorder (ADHD): NICE guideline [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/CG072NiceGuidelineV2.pdf [Accessed 2009 Feb 16]
5. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006 Apr 6; 354 (14): 1445-1448
6. Wilens TE, Prince JB, Spencer TJ, et al. Stimulants and sudden death: What is a physician to do [see comment]? Pediatrics 2006 Sep; 118 (3): 1215-9
7. Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: a scientific statement from the American heart association council on cardiovascular disease in the young congenital cardiac defects committee and the council on cardiovascular nursing. Circulation 2008 May 6; 117 (18): 2407-2423
8. Perrin JM, Friedman RA, Knilans TK; Black Box Working Group, Section on Cardiology and Cardiac, Surgery. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics 2008 Aug; 122 (2): 451-3
9. Kelly KL, Rapport MD, DuPaul GJ. Attention deficit disorder and methylphenidate: a multi-step analysis of doseresponse effects on childrens cardiovascular functioning. Int Clin Psychopharmacol 1988 Apr; 3 (2): 167-181
10. Martin CA, Guenthner G, Bingcang C, et al. Measurement of the subjective effects of methylphenidate in 11- to 15-year-old children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2007 Feb; 17 (1): 63-73
11. Silva R, Muniz R, Pestreich LK, et al. Efficacy of two longacting methylphenidate formulations in children with attention- deficit/hyperactivity disorder in a laboratory classroom setting. J Child Adolesc Psychopharmacol 2005 Aug; 15 (4): 637-654
12. Findling RL, Short EJ, Manos MJ. Short-term cardiovascular effects of methylphenidate and adderall. J Am Acad Child Adolesc Psychiatry 2001 May; 40 (5): 525-9
13. Kratochvil CJ, Heiligenstein JH, Dittmann R, et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry 2002 Jul; 41 (7): 776-784
14. Wilens TE, McBurnett K, Bukstein O, et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/ hyperactivity disorder. Arch Pediatr Adolesc Med 2006 Jan; 160 (1): 82-90
15. McGough JJ, McBurnett K, Bukstein O, et al. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2006 Jun; 16 (3): 351-356
16. Greenhill LL, Findling RL, Swanson JM, ADHD Study Group. A double-blind, placebo-controlled study of modified- release methylphenidate in children with attentiondeficit/ hyperactivity disorder [abstract]. Pediatrics 2002 Mar; 109 (3): E39
17. Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics 2001 Oct; 108 (4): 883-892
18. Findling RL, Short EJ, McNamara NK, et al. Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007 Nov; 46 (11): 1445-1453
19. Findling RL, Quinn D, Hatch SJ, et al. Comparison of the clinical efficacy of twice-daily ritalin and once-daily equasym XL with placebo in children with attention deficit/ hyperactivity disorder. Eur Child Adolesc Psychiatry 2006 Dec; 15 (8): 450-459
20. Gau SS, Shen HY, Soong WT, et al. An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attentiondeficit/ hyperactivity disorder in Taiwan. J Child Adolesc Psychopharmacol 2006 Aug; 16 (4): 441-455
21. SteinMA, Sarampote CS, Waldman ID, et al. A dose-response study of OROS methylphenidate in children with attentiondeficit/hyperactivity disorder [abstract]. Pediatrics 2003 Nov; 112 (5): e404
22. Gadow KD, Sverd J, Sprafkin J, et al. Long-term methylphenidate therapy in children with comorbid attentiondeficit hyperactivity disorder and chronic multiple tic disorder. Arch Gen Psychiatry 1999 Apr; 56 (4): 330-336
23. Wilens TE, Biederman J, Lerner M, Concerta Study Group. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attentiondeficit/ hyperactivity disorder: results from a one-year follow- up study. J Clin Psychopharmacol 2004 Feb; 24 (1): 36-41
24. Wilens T, McBurnett K, Stein M, et al. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry 2005 Oct; 44 (10): 1015-1023
25. Rapport MD, Moffitt C. Attention deficit/hyperactivity disorder and methylphenidate: a review of height/weight, cardiovascular, and somatic complaint side effects. Clin Psychol Rev 2002 Nov; 22 (8): 1107-1131
26. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed. Washington, DC: American Psychiatric Association, 1980
27. Gothelf D, Gruber R, Presburger G, et al. Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study. J Clin Psychiatry 2003 Oct; 64 (10): 1163-1169
28. Lucas PB, Gardner DL, Wolkowitz OM, et al. Methylphenidate- induced cardiac arrhythmias [letter]. N Engl J Med 1986 Dec 4; 315 (23): 1485
29. Medicines and healthcare products regulatory agency. Drug analysis print: methylphenidate [online]. Available from URL: http://www.mhra.gov.uk/ Safetyinformation/Howwemonitorthesafetyofproducts/Medicines/TheYellowCardScheme/ YellowCarddata/Druganalysisprints/CON024109? indexChar=M [Accessed 2008 Oct 28]
30. Safer DJ. Relative cardiovascular safety of psychostimulants used to treat attention-deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 1992; 2 (4): 279-290
31. Prasad S, Furr AJ, Zhang S, et al. Baseline values from the electrocardiograms of children and adolescents withADHD. Child Adolesc Psychiatry Ment Health 2007; 1 (1): 11
32. Ilgenli TF, Congologlu A, Ozturk C, et al. Acute effect of methylphenidate on QT interval duration and dispersion in children with attention deficit hyperactivity disorder. Adv Ther 2007 Jan-Feb; 24 (1): 182-188
33. Rijnbeek PR, Witsenburg M, Schrama E, et al. New normal limits for the paediatric electrocardiogram. Eur Heart J 2001 Apr; 22 (8): 702-711
34. Rappley MD, Moore JW, Dokken D. ADHD drugs and cardiovascular risk [author reply]. N Engl JMed 2006 May 25; 354 (21): 2296-8
35. Knight M. Stimulant-drug therapy for attention-deficit disorder (with or without hyperactivity) and sudden cardiac death. Pediatrics 2007 Jan; 119 (1): 154-5
36. Gould M, Walsh BT, Munfakh JL, et al. Sudden death and use of stimulant medications in youths. Am J Psychiatry. Epub 2009 Jun 15
37. Food and Drug Administration. Communication about ongoing safety review of stimulant medications used in children with attention deficit hyperactivity disorder [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathc
38. McCarthy S, Cranswick N, Potts L, et al. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the General Practice Research Database. Drug Saf 2009; 32 (11): 1089-1096
39. Besag FMC. Attention-deficity hyperactivity disorder (ADHD) treatment and sudden death. Druf Saf 2009; 32 (11): 1097-1100
40. Samuels JA, Franco K, Wan F, et al. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol 2006 Jan; 21 (1): 92-95
41. Spencer TJ, Biederman J, Wilens TE. Efficacy and tolerability of long-term, open-label, mixed amphetamine salts extended release in adolescents with ADHD. CNS Spectr 2005 Oct; 10 (10 Suppl. 15): 14-21
42. Biederman J, Lopez FA, Boellner SW, et al. A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics 2002 Aug; 110 (2 Pt 1): 258-66
43. Findling RL, Biederman J, Wilens TE, et al. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr 2005 Sep; 147 (3): 348-354
44. Wilens TE, Spencer TJ, Biederman J. Short- and long-term cardiovascular effects of mixed amphetamine salts extended- release in adolescents with ADHD. CNS Spectr 2005 Oct; 10 (10 Suppl. 15): 22-30
45. Biederman J, Krishnan S, Zhang Y, et al. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/ hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther 2007 Mar; 29 (3): 450-63
46. Donner R, Michaels MA, Ambrosini PJ. Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit/ hyperactivity disorder. Biol Psychiatry 2007 Mar 1; 61 (5): 706-712
47. Findling RL, Childress AC, Krishnan S, et al. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectr 2008 Jul; 13 (7): 614-620
48. Spencer TJ, Wilens TE, Biederman J, et al. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006 Feb; 28 (2): 266-79
49. Kratochvil CJ, Wilens TE, Greenhill LL, et al. Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006 Aug; 45 (8): 919-927
50. Medicines and healthcare products regulatory agency. Drug analysis print: dexamphetamine [online]. Available from URL: http://www.mhra.gov.uk/ Safetyinformation/Howwemonitorthesafetyofproducts/Medicines/TheYellowCardScheme/ YellowCarddata/Druganalysisprints/CON024109?indexChar=D [Accessed 2008 Oct 6]
51. Kelly RP, Yeo KP, Teng CH, et al. Hemodynamic effects of acute administration of atomoxetine and methylphenidate. J Clin Pharmacol 2005 Jul; 45 (7): 851-855
52. Stojanovski SD, Robinson RF, Baker SD, et al. Children and adolescent exposures to atomoxetine hydrochloride reported to a poison control center. Clin Toxicol (Phila) 2006; 44 (3): 243-247
53. Spencer T, Biederman J, Heiligenstein J, et al. An openlabel, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001; 11 (3): 251-265
54. Wernicke JF, Faries D, Girod D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 2003; 26 (10): 729-740
55. Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002 Dec; 63 (12): 1140-1147
56. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attentiondeficit/ hyperactivity disorder: a randomized, placebo-controlled, dose-response study [abstract]. Pediatrics 2001 Nov; 108 (5): E83
57. Michelson D, Read HA, Ruff DD, et al. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2007 Feb; 46 (2): 242-251
58. Allen AJ, Kurlan RM, Gilbert DL, et al. Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 2005 Dec 27; 65 (12): 1941-1949
59. Donnelly C, Bangs M, Trzepacz P, et al. Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2009; 48 (2): 176-185
60. Wilens TE, Newcorn JH, Kratochvil CJ, et al. Long-term atomoxetine treatment in adolescents with attention-deficit/ hyperactivity disorder. J Pediatr 2006 Jul; 149 (1): 112-119
61. Dworkin N. Increased blood pressure and atomoxetine [abstract]. J Am Acad Child Adolesc Psychiatry 2005 Jun; 44 (6): 510
62. National Heart Lung and Blood Institute. Report of the second task force on blood pressure control in children - 1987: task force on blood pressure control in children. National Heart, Lung and Blood Institute, Bethesda, Mayland. Pediatrics 1987; 79: 1-25
63. Shibao C, Raj SR, Gamboa A, et al. Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. Hypertension 2007 Jul; 50 (1): 47-53
64. Medicines and Healthcare Products Regulatory Agency. Straterra (atomoxetine): preliminary assessment report December 2005 [online]. Available from URL: http://www.mhra.gov.uk/home/groups/es-foi/documents/foidisclosure/ con2024013.pdf [Accessed 2009 Jan 16]
65. Sawant S, Daviss SR. Seizures and prolonged QTc with atomoxetine overdose [abstract]. Am J Psychiatry 2004 Apr; 161 (4): 757
66. Rajesh AS, Bates G, Wright JG. Atomoxetine-induced electrocardiogram changes. Arch Dis Child 2006 Dec; 91 (12): 1023-1024
67. Graham J, Coghill D. Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. CNS Drugs 2008; 22 (3): 213-237
68. Medicines and Healthcare Products Regulatory Agency. Drug analysis print: atomoxetine [online]. Available from URL: http://www.mhra.gov.uk/ Safetyinformation/Howwemonitorthesafetyofproducts/Medicines/TheYellowCardScheme/ YellowCarddata/Druganalysisprints/CON024109?indexChar=A [Accessed 2008 Oct 23
69. American Academy of Pediatrics/American Heart Association. American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: May 16, 2008. J Dev Behav Pediatr 2008 Aug; 29 (4): 335